1. A method in a wireless terminal in a Long Term Evolution (LTE) system, comprising:
sending a layer 1 indication using a first uplink transmission resource to request a second uplink transmission resource;
wherein the layer 1 indication is an ACKNACK transmission.
2. The method of claim 1, further comprising resending a request for the second uplink transmission resource.
3. The method of claim 1, further comprising resending a request for the second uplink transmission resource using the first uplink transmission resource.
4. The method of claim 3, further comprising releasing the first uplink transmission resource after resending the request for the second uplink transmission resource.
5. The method of claim 1, further comprising: sending the ACKNACK transmission over a Scheduling Request (SR) resource.
6. The method of claim 1, wherein the layer 1 indication indicates an ACKNACK and a Scheduling Request.
7. The method of claim 6, wherein the Scheduling Request is a State Transition indication.
8. The method of claim 5, wherein transmitting a \u201c1\u201d indicates a NACK and a Scheduling Request.
9. The method of claim 5, wherein transmitting a \u201c\u22121\u201d indicates an ACK and a Scheduling Request.
10. The method of claim 5, wherein transmitting a positive value indicates a NACK and a Scheduling Request.
11. The method of claim 5, wherein transmitting a negative value indicates an ACK and a Scheduling Request.
12. The method of claim 1, wherein the layer 1 indication is a single bit indication.
13. A method in a wireless terminal in a Long Term Evolution (LTE) system, comprising:
receiving a configuration of a first uplink transmission resource; and
sending a layer 1 indication according to the received configuration,
wherein the layer 1 indication is an ACKNACK transmission that also indicates a Scheduling Request.
14. The method of claim 13, wherein the layer 1 indication is an ACKNACK transmission transmitted over a Scheduling Request resource.
15. The method of claim 13, wherein the Scheduling Request is a State Transition indication.
16. A method in a wireless terminal in a Long Term Evolution (LTE) system, comprising:
receiving a configuration of a first uplink transmission resource; and
sending a layer 1 indication using the first uplink transmission resource;
wherein the layer 1 indication is an ACKNACK transmission that also indicates a Scheduling Request.
17. The method of claim 16, wherein the layer 1 indication includes a positive value to indicate a Scheduling Request and a NACK.
18. The method of claim 16, wherein the layer 1 indication includes a negative value to indicate a Scheduling Request and an ACK.
19. A method on a network element comprising:
receiving a layer 1 indication on a first uplink transmission resource, the layer 1 indication requesting a second uplink transmission resource;
wherein the layer 1 indication is an ACKNACK transmission.
20. The method of claim 19, wherein the first uplink transmission resource is a Scheduling Request resource.
21. The method of claim 19, wherein the received layer 1 indication indicates both a Scheduling Request and an ACKNACK.
22. The method of claim 21, wherein the Scheduling Request is a State Transition indication.
23. The method of claim 19, wherein receiving a negative value indicates a Scheduling Request and an ACK.
24. The method of claim 19, wherein receiving a positive value indicates a Scheduling Request and a NACK
25. The method of claim 19, wherein receiving a \u201c1\u201d indicates a NACK and a Scheduling Request.
26. The method of claim 19, wherein receiving a \u201c\u22121\u201d indicates an ACK and a Scheduling Request.
27. The method of claim 19, wherein the layer 1 indication is a single bit indication.
28. The method of claim 19, wherein the network element is an eNB.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
We claim:
1. A compound of the formula (I):
4
wherein:
R3 is selected from the group consisting of 1-napthyl, 2-napthyl and cycloalkylphenyl; and
R4 and R5 are taken together to form a ring having 5 to 10 carbon atoms.
2. The compound of claim 1 wherein said cycloalkylphenyl is cyclohexylphenyl.
3. The compound of claim 1 wherein said 1-napthyl and 2-napthyl are substituted.
4. The compound of claim 3 wherein said 1-napthyl and 2-napthyl are substituted with one or more (C1-C6)alkyl groups, (C2-C6)alkenyl groups, (C1-C6)alkanoyl groups, (C1-C6)alkanoyloxy groups, (C3-C6) cycloalkyl groups, (C3-C6) cycloalkenyl groups, halo (C1-C6)alkyl groups, (C1-C6)alkoxy groups, (C1-C6)alkoxycarbonyl groups, (C3-C6)cycloalkyl(C1-C6)alkyl groups, (C2-C6)alkynyl groups or halogens.
5. The compound of claim 1 wherein said ring has 5 carbon atoms.
6. A method for enhancing adenosine A1 receptors in a mammal, including a human, by administering to said mammal an effective amount of a compound of formula (I):
5
wherein:
R3 is selected from the group consisting of 1-napthyl, 2-napthyl and cycloalkylphenyl; and
R4 and R5 are taken together to form a ring having 5 to 10 ring atoms.
7. The method of claim 6 wherein said cycloalkylbenzoyl is cyclohexylphenyl.
8. The method of claim 6 wherein said 1-napthyl and 2-napthyl are substituted.
9. The method of claim 8 wherein wherein said 1-napthyl and 2-napthyl are substituted with one or more (C1-C6)alkyl groups, (C2-C6)alkenyl groups, (C1-C6)alkanoyl groups, (C1-C6)alkanoyloxy groups, (C3-C6) cycloalkyl groups, (C3-C6) cycloalkenyl groups, halo (C1-C6)alkyl groups, (C1-C6)alkoxy groups, (C1-C6)alkoxycarbonyl groups, (C3-C6)cycloalkyl(C1-C6)alkyl groups, (C2-C6)alkynyl groups or halogens.
10. The method of claim 6 wherein said ring has 5 carbon atoms.
11. A method for promoting angiogenesis in a mammal, including a human, by administering to said mammal an effective amount of a compound of formula (I):
6
wherein:
R3 is selected from the group consisting of 1-napthyl, 2-napthyl and cycloalkylphenyl; and
R4 and R5 are taken together to form a ring having about 5 to about 10 ring atoms.
12. The method of claim 11 wherein said cycloalkylphenyl is cyclohexylphenyl.
13. The method of claim 11 wherein said 1-napthyl and 2-napthyl are substitued.
14. The method of claim 13 wherein said 1-napthyl and 2-napthyl are substituted with one or more (C1-C6)alkyl groups, (C2-C6)alkenyl groups, (C1-C6)alkanoyl groups, (C1-C6)alkanoyloxy groups, (C3-C6) cycloalkyl groups, (C3-C6) cycloalkenyl groups, halo (C1-C6)alkyl groups, (C1-C6)alkoxy groups, (C1-C6)alkoxycarbonyl groups, (C3-C6)cycloalkyl(C1-C6)alkyl groups, (C2-C6)alkynyl groups or halogens.
15. The method of claim 11 wherein said ring has 5 carbon atoms.
16. A method of treating ischemic disease in a mammal, including a human, by administering to said mammal an effective amount of a compound of formula (I):
7
wherein:
R3 is selected from the group consisting of 1-napthyl, 2-napthyl and cycloalkylphenyl; and
R4 and R5 are taken together form a ring having about 5 to about 10 ring atoms.
17. The method of claim 16 wherein said cycloalkylphenyl is cyclohexylphenyl.
18. The method of claim 16 wherein said 1-napthyl and 2-napthyl are substitued.
19. The method of claim 18 wherein said 1-napthyl and 2-napthyl are substituted with one or more (C1-C6)alkyl groups, (C2-C6)alkenyl groups, (C1-C6)alkanoyl groups, (C1-C6)alkanoyloxy groups, (C3-C6) cycloalkyl groups, (C3-C6) cycloalkenyl groups, halo (C1-C6)alkyl groups, (C1-C6)alkoxy groups, (C1-C6)alkoxycarbonyl groups, (C3-C6)cycloalkyl(C1-C6)alkyl groups, (C2-C6)alkynyl groups or halogens.
20. The method of claim 16 wherein said ring has 5 carbon atoms.
21. The method of claim 16 wherein said ischemic disease is selected from the group consisting of: heart disease, stroke and peripheral vascular disease.
22. A method of treating cardiac arrhythmias in a mammal, including a human, by administering to said mammal an effective amount of the compound of claim 1.
23. A method of treating chronic pain in a mammal, including a human, by administering to said mammal an effective amount of the compound of claim 1.
24. A method of inducing sleep in a mammal, including a human, by administering to said mammal an effective amount of the compound of claim 1.